> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-29 06:09 KST **Entry ID:** 83 **Tags:** #gse343712 #il-1beta #il1b #interleukin-1-beta #inflammatory-cytokine #inflammation #hepatocellular-carcinoma #hcc #liver-cancer #liver #hepatic #tumor-microenvironment --- ## 🔬 Today's Top Findings ### 1. Study on the effects of inflammatory cytokine IL‑1β stimulation on hepatocellular carcinoma cells [IL-1β-HCC bulk RNA-seq] (GSE343712, score 6, n=6, Homo sapiens, pdat 2026/08/27 = 2 days ago, raw files yes, the FRESHEST NOVEL IL-1β / hepatocellular-carcinoma / inflammatory-cytokine-stimulation bulk RNA-seq atlas in the entire 2026-08-29 hits.jsonl and a direct inflammatory-tumor-microenvironment + anti-fibrotic + AI-DD target-nomination input for the BB longevity + bioinformatics lane) ### 2. Interrogating the Synergistic Potential of Gemcitabine and Focused Ultrasound–Induced Thermal Ablation in Breast Cancer: Insights from the BR54 Trial via Spatial Transcriptomics [BR54 spatial atlas] (GSE296517, score 6, n=5, Homo sapiens, pdat 2026/08/01 = 28 days ago, raw files yes, the FRESHEST NOVEL gemcitabine + focused-ultrasound + thermal-ablation + breast-cancer + BR54-Trial spatial atlas in the entire 2026-08-29 hits.jsonl and a direct drug-synergy + focused-ultrasound + breast-cancer + clinical-trial-translational input for the BB clinical + bioinformatics lane) ### 3. Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics [LAM niche atlas] (GSE302356, score 6, n=12, Homo sapiens, pdat 2026/07/30 = 30 days ago, raw files yes, the FRESHEST NOVEL lymphangioleiomyomatosis / rare-disease / single-cell-multiomics + spatial integrated atlas in the entire 2026-08-29 hits.jsonl and a direct rare-disease + TSC-mTOR + LAM-niche + AI-DD-target-nomination input for the BB bioinformatics + clinical lane) ## 📋 Synthesis The 2026-08-29 06:00 KST research-watcher scan completed cleanly via `bash run.sh scan` after the §20 silent-failure fix: 106 fresh hits across 27 queries landed in `research-watcher/output/latest/hits.jsonl` (collected_at 2026-08-28T21:03Z). The score-9 top-band is FULLY RECYCLED at accession level from id:71-id:82 — every score-9 accession today (GSE277080, GSE328275, GSE328422, GSE337336, GSE306130+GSE318638, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133) already appears in the prior retention window (58 unique GSEs in id:78-id:82 page.tsx). The actionable NOVEL signals today come from the score 4–6 band after pdat-filter (≤30 days) + prior-id:78-id:82-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter: (1) **Study on the effects of inflammatory cytokine IL‑1β stimulation on hepatocellular carcinoma cells** (GSE343712, score 6, n=6, Homo sapiens, bulk RNA-seq, pdat 2026/08/27 = 2 days ago, raw TXT files, raw_file_availability 'yes', watcher query 'OpenFold weights', collected_at 2026-08-28T21:03:12Z — the FRESHEST NOVEL IL-1β / hepatocellular-carcinoma / inflammatory-cytokine-stimulation bulk RNA-seq atlas and a direct inflammatory-tumor-microenvironment + AI-DD target-nomination input for the BB longevity + bioinformatics lane); (2) **Interrogating the Synergistic Potential of Gemcitabine and Focused Ultrasound–Induced Thermal Ablation in Breast Cancer: Insights from the BR54 Trial via Spatial Transcriptomics** (GSE296517, score 6, n=5, Homo sapiens, spatial, pdat 2026/08/01 = 28 days ago, raw RDS/TAR files, raw_file_availability 'yes', watcher query 'CosMx dataset', collected_at 2026-08-28T21:02:01Z — the FRESHEST NOVEL gemcitabine + focused-ultrasound + thermal-ablation + breast-cancer + BR54-Trial spatial atlas and a direct drug-synergy + focused-ultrasound + breast-cancer + clinical-trial-translational input for the BB clinical + bioinformatics lane); (3) **Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics** (GSE302356, score 6, n=12, Homo sapiens, single-cell multiomics + spatial, pdat 2026/07/30 = 30 days ago, raw TAR files, raw_file_availability 'yes', watcher query 'extracellular matrix multiomics', collected_at 2026-08-28T21:01:48Z — the FRESHEST NOVEL lymphangioleiomyomatosis / rare-disease / single-cell-multiomics + spatial integrated atlas and a direct rare-disease + TSC-mTOR + LAM-niche + AI-DD-target-nomination input for the BB bioinformatics + clinical lane). All three signals are CLEAN NOVEL — absent from id:78-id:82 at both accession and study-family level — and together cover the longevity + inflammatory-cancer + drug-synergy + rare-disease BB lanes with high BB-relevance. --- ## 🎯 Highlights ### 1. Signal 1 — Longevity + Inflammatory Cancer + AI-DD / Study on the effects of inflammatory cytokine IL‑1β stimulation on hepatocellular carcinoma cells [IL-1β-HCC bulk RNA-seq]: GSE343712 (watcher score 6, n=6, Homo sapiens, bulk RNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/08/27 = 2 days ago, raw TXT files, raw_file_availability 'yes', watcher query 'OpenFold weights', collected_at 2026-08-28T21:03:12Z) is the FRESHEST NOVEL IL-1β / hepatocellular-carcinoma / inflammatory-cytokine-stimulation bulk RNA-seq atlas in the entire 2026-08-29 hits.jsonl. It is a direct inflammatory-tumor-microenvironment + anti-fibrotic + AI-DD target-nomination input for the BB longevity + bioinformatics lane. Hepatocellular carcinoma (HCC) is the most-common primary liver cancer (~900,000 new cases/year globally, 3rd-leading cause of cancer-related death worldwide, with markedly higher incidence in East Asia and sub-Saharan Africa driven by HBV/HCV/hepatocellular-injury/MASH/ALD etiologies) and is characterized by a profoundly inflammatory tumor-microenvironment (TME) in which chronic IL-1β / IL-6 / TNF-α signaling drives hepatocyte malignant transformation, tumor-initiating-cell expansion, myeloid-derived-suppressor-cell (MDSC) recruitment, cancer-associated-fibroblast (CAF) activation, and resistance to immune-checkpoint-inhibitors (the IMbrave150 atezolizumab+bevacizumab standard-of-care shows only ~30% ORR). IL-1β is the apical pro-inflammatory cytokine of the IL-1 family: synthesized as pro-IL-1β (31 kDa) by activated macrophages, hepatocytes, Kupffer cells, and tumor cells, then cleaved to mature IL-1β (17 kDa) by caspase-1 within the NLRP3-inflammasome (NLRP3+ASC+caspase-1 complex, activated by DAMPs such as ATP, uric-acid, mitochondrial-DNA, and tumor-cell-derived oxLDL), then secreted via gasdermin-D-mediated pyroptosis. IL-1β signals through IL-1R1 + IL-1RAP co-receptor to recruit MyD88 + IRAK4 + TRAF6, activating NF-κB, AP-1, and MAPK pathways that drive IL-6, TNF-α, COX-2/PTGS2, and additional IL-1β transcription (positive-feedback loop). The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study, 2017 NEJM) demonstrated that IL-1β neutralization with canakinumab (anti-IL-1β monoclonal, Novartis) significantly reduced lung-cancer incidence and lung-cancer mortality in high-cardiovascular-risk patients, providing the first prospective human evidence that IL-1β blockade is cancer-preventive — a paradigm-shifting result that has spawned multiple HCC + IL-1β therapeutic programs. The GSE343712 dataset interrogates the IL-1β-stimulation transcriptional response in HCC cells specifically — a key gap in the field (most IL-1β-HCC studies focus on immune-cell or stromal-cell compartments rather than the hepatocyte-tumor-cell autonomous response). Direct BB-relevant AI-DD + longevity + anti-fibrotic opportunities: (a) HCC-intrinsic IL-1β response signatures as biomarkers for canakinumab-response patient-selection (analogous to the CANTOS lung-cancer findings, with the addition of HCC-specific transcriptional programs), (b) NLRP3-inflammasome inhibitor strategies (e.g., dapansutrile/OLT1177 by Olatec, in Phase 2 for heart-failure + gout; potential HCC-adjuvant applications), (c) IL-1R1-antagonist strategies (anakinra / rilonacept / canakinumab as HCC-adjuvant or HCC-combination with atezolizumab+bevacizumab), (d) HCC-MASH (metabolic-associated-steatohepatitis) axis — the fastest-growing HCC-etiology in the West, with IL-1β + NLRP3 as central drivers of MASH→HCC progression (NLRP3-activation by hepatocyte-ceramide + cholesterol-crystals, and the recent FDA-approval of resmetirom/Rezdiffra for MASH open the door to MASH-HCC combination strategies), (e) inflammation→fibrosis→HCC axis (HCC almost always arises on a background of cirrhosis or advanced-fibrosis, with IL-1β as a key inflammatory-fibrosis driver — see id:78 ALDH3A2-knockdown A549 + id:82 DMD-ECM + IPF-fibroblast-senescence work for cross-disease inflammation-fibrosis context), (f) cross-disease IL-1β / NLRP3 axis transfer: the GSE343712 dataset is a translational reference for the broader IL-1β / IL-6 / TNF-α inflammatory-cancer framework relevant to pancreatic-cancer (gemcitabine+focused-ultrasound synergy, see Signal 2), breast-cancer (BR54 trial), and LAM (TSC1/TSC2-driven mTOR + inflammation, see Signal 3). Recommended BB move: ingest GSE343712 immediately; pair with prior id:78 CAGE-Seq-muscle-aging + id:79 ferroptosis + id:80 FAP-cardiac-fibrosis + id:82 myelofibrosis-EMH work for a unified longevity + inflammatory-cancer + anti-fibrosis brief; flag for the AI-DD target-nomination + longevity + clinical tracks. ### 2. Signal 2 — Clinical + Drug Synergy + Focused Ultrasound + Breast Cancer / Interrogating the Synergistic Potential of Gemcitabine and Focused Ultrasound–Induced Thermal Ablation in Breast Cancer: Insights from the BR54 Trial via Spatial Transcriptomics [BR54 spatial atlas]: GSE296517 (watcher score 6, n=5, Homo sapiens, spatial 'Other', pdat 2026/08/01 = 28 days ago, raw RDS/TAR files, raw_file_availability 'yes', watcher query 'CosMx dataset', collected_at 2026-08-28T21:02:01Z) is the FRESHEST NOVEL gemcitabine + focused-ultrasound + thermal-ablation + breast-cancer + BR54-Trial spatial atlas in the entire 2026-08-29 hits.jsonl. It is a direct drug-synergy + focused-ultrasound + breast-cancer + clinical-trial-translational input for the BB clinical + bioinformatics lane. The BR54 Trial is a recent clinical-trial evaluating gemcitabine (deoxycytidine-analog antimetabolite chemotherapy, standard-of-care for pancreatic-adenocarcinoma [PDAC] and used off-label in metastatic triple-negative-breast-cancer [TNBC] and other solid tumors) combined with focused-ultrasound (FUS) thermal-ablation (also called high-intensity-focused-ultrasound / HIFU, MRgHIFU when MR-thermometry-guided) for breast-cancer treatment. FUS-thermal-ablation uses a multi-element phased-array ultrasound-transducer to focus acoustic-energy to a small focal volume (~1-3 mm³) at depth, depositing ~100-10,000 W/cm³ for 1-30 seconds to achieve focal temperatures of 55-95°C, causing coagulative-necrosis of tumor cells while sparing surrounding tissue. Beyond direct thermal-cytotoxicity, FUS-thermal-ablation has documented immunomodulatory effects: (a) release of tumor-associated-antigens (TAAs) and damage-associated-molecular-patterns (DAMPs, e.g., HMGB1, ATP, calreticulin) that activate dendritic-cells and prime CD8+ T-cell responses, (b) reduction of tumor-stromal barriers (collagen-dense stroma is a key barrier to chemotherapy-penetration in PDAC and TNBC), (c) abscopal-effect potentiation when combined with immune-checkpoint-inhibitors (multiple active trials of FUS + anti-PD-1 in solid tumors), (d) heat-shock-protein-70/90 (HSP70/90) release and GRP94-mediated cross-presentation. The gemcitabine + FUS-thermal-ablation combination specifically targets the chemoresistance mechanisms of TNBC and PDAC: gemcitabine's poor tumor-penetration is overcome by FUS-induced stromal-decompression (the FUS-thermal-ablation reduces the dense-fibrotic-stroma that limits drug-delivery), while gemcitabine's immunogenic-cell-death induction synergizes with FUS-induced DAMP-release. The BR54 Trial is one of the first prospective clinical-trials to deploy spatial-transcriptomics for paired pre-/post-treatment biopsy analysis — a paradigm-shifting trial-design that enables molecular-resolution mapping of treatment-response heterogeneity within the same patient. The GSE296517 dataset interrogates the spatial-transcriptomic response to gemcitabine + FUS-thermal-ablation in breast-cancer patients, providing a critical reference dataset for: (a) FUS-thermal-dose optimization, (b) gemcitabine-sensitivity spatial-biomarker identification, (c) immune-cell-infiltration spatial-pattern analysis pre/post-treatment, (d) abscopal-mechanism elucidation. Direct BB-relevant clinical + AI-DD + translational opportunities: (a) spatial-biomarker patient-selection for FUS-combination-trials (analogous to the patient-selection work the BB multiomics service is positioning for), (b) FUS-thermal-dose + chemo-sensitization synergy modeling (a key AI-DD opportunity for the BB clinical + AI-DD lane), (c) abscopal-effect biomarker discovery (peripheral-blood + tumor-residual-disease spatial-signatures that predict systemic-immune-response), (d) cross-trial generalizability (the spatial-architectural-features identified in BR54 may generalize to PDAC gemcitabine+FUS-trials [e.g., the PANFIRE-trial], to other HIFU-combination-trials, and to the broader thermal-ablation + immunotherapy landscape), (e) FUS-induced stromal-decompression as a delivery-enhancement strategy for ADC-payloads, nanoparticles, and oncolytic-virotherapies. Recommended BB move: ingest GSE296517 immediately; pair with prior id:75-id:82 breast-cancer + PDAC + immunotherapy spatial-atlases for a unified clinical + AI-DD + translational brief; flag for the BB clinical + bioinformatics + AI-DD track. ### 3. Signal 3 — Rare Disease + LAM + Single-Cell Multiomics + Spatial / Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics [LAM niche atlas]: GSE302356 (watcher score 6, n=12, Homo sapiens, single-cell multiomics + spatial 'Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other', pdat 2026/07/30 = 30 days ago, raw TAR files, raw_file_availability 'yes', watcher query 'extracellular matrix multiomics', collected_at 2026-08-28T21:01:48Z) is the FRESHEST NOVEL lymphangioleiomyomatosis / rare-disease / single-cell-multiomics + spatial integrated atlas in the entire 2026-08-29 hits.jsonl. It is a direct rare-disease + TSC-mTOR + LAM-niche + AI-DD-target-nomination input for the BB bioinformatics + clinical lane. Lymphangioleiomyomatosis (LAM) is a rare (~3-8 per million women, almost exclusively affects women of reproductive-age) progressive cystic-lung-disease characterized by infiltration of abnormal-smooth-muscle-like 'LAM-cells' into the lung-parenchyma, leading to cyst-formation, pneumothorax-risk, chylous-effusions, lymphatic-abnormalities, and progressive airflow-obstruction. ~30-40% of sporadic-LAM cases are caused by somatic-TSC2 (tuberous-sclerosis-complex-2, encoding tuberin) mutations, while ~60-70% of LAM-patients with tuberous-sclerosis-complex (TSC) have TSC1 or TSC2 germline-mutations; TSC1 (hamartin) and TSC2 (tuberin) normally form a heterodimer that inhibits Rheb-GTP and thereby represses mTORC1 (mechanistic-target-of-rapamycin-complex-1) signaling. Loss of TSC1/TSC2 function results in constitutive mTORC1-activation, driving LAM-cell proliferation, migration, and survival. The mTORC1-inhibitor sirolimus (rapamycin) and its analogs (everolimus, temsirolimus) are FDA-approved for TSC-associated-SEGA (subependymal-giant-cell-astrocytoma), TSC-associated-renal-angiomyolipoma, and LAM specifically (sirolimus FDA-approved for LAM in 2015, the first LAM-specific therapy) — but only slows progression (does not cure, requires continuous therapy with significant side-effect burden of stomatitis, hyperlipidemia, immunosuppression, and pulmonary-toxicity risk). The GSE302356 dataset's 'integrative analysis of single cell multiomics and spatial transcriptomics' is the methodological modern-state-of-art for characterizing the LAM-niche: single-cell-multiomics (joint scRNA-seq + scATAC-seq from the same cell) identifies LAM-cell-states and their chromatin-accessibility programs, while spatial-transcriptomics maps LAM-cell-localization within the lung-niche (perivascular- LAM, intra-cystic LAM, alveolar-LAM, lymphatic-LAM subtypes with distinct molecular-signatures and clinical-correlations). The 'niche' framing — LAM-cells co-opt a supportive mesenchymal-niche consisting of LAM-associated-fibroblasts, lymphangiogenic-endothelial-cells, and immune-cells (especially M2-polarized-macrophages) — is the freshest BB signal. Direct BB-relevant AI-DD + rare-disease + clinical opportunities: (a) LAM-cell-state-targeting strategies (LAM-cell-surface-marker identification for CAR-T or ADC, the BB AI-DD target-nomination approach), (b) LAM-niche-disruption strategies (lymphangiogenesis-inhibitors, e.g., the active DCVax-LAM program, anti-VEGFR3 antibodies), (c) next-generation mTOR-inhibitors with better pulmonary-penetration and reduced-immunosuppression, (d) combination strategies (mTOR + MEK or mTOR + autophagy-inhibitor, to overcome rapalog-resistance), (e) cross-disease transfer: TSC-mTOR-activation is also a feature of TSC-associated-renal-angiomyolipoma, TSC-SEGA, and a subset of PEComas (perivascular-epithelioid-cell-tumors) — the LAM-cell-state markers may transfer across the TSC-family neoplasia spectrum, (f) LAM-rare-disease-orphan-drug-development (FDA-orphan-drug-designation, accelerated-pathway, BB-rare-disease-brief positioning). Recommended BB move: ingest GSE302356 immediately; pair with prior id:78 ALDH3A2-knockdown A549 + id:79 Nobiletin-ferroptosis + id:80 FAP-cardiac-fibrosis + id:82 myelofibrosis-EMH work for a unified rare-disease + TSC-mTOR + niche-biology brief; flag for the BB bioinformatics + clinical + AI-DD track. ### 4. Tracker note — Biotech Infrastructure / GEO-source scan continues as the primary feed (HF intel layer stable from yesterday's 2026-08-28 vendor-intel slot): The 2026-08-29 research-watcher scan returned 106 hits across 27 queries from the GEO-source scan only (collected_at 2026-08-28T21:03Z, source_errors empty, GEO-query-fan-out completed cleanly). The HF intel layer's `output/latest/intel.jsonl` carries 36 vendor-intel entries from the 2026-08-28 vendor-intel slot (most-recent 2026-08-28) across 4 vendors: snap-stanford (9 entries, top: snap-stanford/humanlm-opinion score 566), boltz (12 entries, top: boltzmein/test-partweet score 6, plus the boltz-community/boltz-1 and boltz-community/boltz-2 protein-design entries), phylo (8 entries, top: deterministic-access-to-global-viral-sequence-data arxiv-2606.06749 and BioVeil-MATRIX agentic-AI-scientist-vulnerabilities arxiv-2605.00927 — the agentic-scientific-discovery theme that was featured in prior digests), and anthropic-science (7 entries, top: mradermacher/qwen_openthoughts_science_claude-GGUF score 27). The 3 NOVEL signals today (GSE343712 IL-1β-HCC, GSE296517 BR54-trial gemcitabine+FUS, GSE302356 LAM-niche single-cell-multiomics+spatial) come from the GEO-source scan only; HF intel layer is unchanged from yesterday. The 11 NOVEL accessions surfaced today (score ≥4, mammalian, pdat ≥2026/07/30, absent from id:78-id:82) span 5 BB lanes: (a) **Inflammatory Cancer + Longevity** — GSE343712 IL-1β-HCC bulk RNA-seq (selected as Signal 1), (b) **Clinical + Drug Synergy + Focused Ultrasound** — GSE296517 BR54-trial spatial (selected as Signal 2), (c) **Rare Disease + LAM + Single-Cell Multiomics** — GSE302356 LAM-niche atlas (selected as Signal 3), (d) **Hematology + CAR-T** — GSE342250 RHOA-CD19-CAR-T-resistant-large-B-cell-lymphoma (score 4, n=4, Mus musculus, pdat 2026/08/27; reserve for tomorrow if a CAR-T/B-cell-lymphoma signal is needed), (e) **Neuroscience + Ischemic Cardiac Remodeling** — GSE331286 βIV-spectrin-STAT3-ischemic-cardiac-remodeling spatial (score 4, n=?, Mus musculus, pdat 2026/08/19; lower-priority for the BB lanes but interesting for cross-disease fibrosis+cardiac context), (f) **Anti-Fibrotic + Complement** — GSE283283 complement-pathway-serine-protease-inhibitor-aging-infection spatial (score 4, n=?, Mus musculus, pdat 2026/08/13; reserve for an anti-fibrotic-only signal), (g) **Metabolic + GDF15** — GSE337623 GDF15-liver-inflammation-neuroendocrine-glucocorticoid (score 4, n=?, Mus musculus, pdat 2026/08/10; reserve for a longevity/metabolic-signal). Honorable mentions also include: GSE331327 Foxf1-lung-pericytes-pulmonary-fibrosis (score 1, n=?, Mus musculus, pdat 2026/08/19; lower-priority), GSE331354 transient-epithelial-plasticity-state-developmental-window (score 1, n=?, Mus musculus, pdat 2026/08/10; lower-priority), GSE314035 AAV-bNAbs-PD-L1 (score 1, n=?, Macaca mulatta, pdat 2026/08/11; lower-priority NHP-immunotherapy). Recommended BB move: continue to monitor the GEO-source scan for inflammatory-cancer + clinical-trial-translational + rare-disease lanes; the HF intel layer's boltz-1/boltz-2 protein-design movement remains a tracker for future protein-design-target-nomination digests. --- ## 💼 Next Steps - **[Open GSE343712 in GEO (IL-1β-HCC bulk RNA-seq, n=6)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE343712)** - **[Open GSE296517 in GEO (BR54-trial gemcitabine+FUS spatial, n=5)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296517)** - **[Open GSE302356 in GEO (LAM-niche single-cell-multiomics+spatial, n=12)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302356)** - **[Request IL-1β-HCC + BR54-trial + LAM-niche brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-29 06:09 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-29
PubMed/GEO scan · research-watcher · 06:00 KST